SRR8518305
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.610
- INTERFERON_GAMMA_RESPONSE+0.570
- ALLOGRAFT_REJECTION+0.490
- IL6_JAK_STAT3_SIGNALING+0.400
- COMPLEMENT+0.290
- INFLAMMATORY_RESPONSE+0.270
- IL2_STAT5_SIGNALING+0.260
- KRAS_SIGNALING_UP+0.090
- HEME_METABOLISM+0.070
- WNT_BETA_CATENIN_SIGNALING+0.070
Top 10 suppressed
- CHOLESTEROL_HOMEOSTASIS-0.450
- ESTROGEN_RESPONSE_EARLY-0.440
- NOTCH_SIGNALING-0.440
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.400
- MYC_TARGETS_V1-0.390
- OXIDATIVE_PHOSPHORYLATION-0.390
- ESTROGEN_RESPONSE_LATE-0.370
- E2F_TARGETS-0.290
- G2M_CHECKPOINT-0.290
- MTORC1_SIGNALING-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-AO-A0JC-01A-11R-A056-07 | — | D | 0.882 |
| 2 | ERR4976617 | — | D | 0.877 |
| 3 | SRR8518220 | — | D | 0.861 |
| 4 | SRR8518255 | — | D | 0.858 |
| 5 | TCGA-E9-A2JT-01A-22R-A18M-07 | — | D | 0.858 |
| 6 | SRR8518166 | — | D | 0.857 |
| 7 | SRR8613700 | — | D | 0.856 |
| 8 | be8d8236-4ebc-46de-a4fd-a901fec1cdce | — | — | 0.856 |
| 9 | SRR1313132 | — | D | 0.853 |
| 10 | ERR4976618 | — | D | 0.848 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.610 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.570 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.490 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.400 | Inavolisib | — uncovered |
| COMPLEMENT | 0.290 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.270 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.260 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.090 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.070 | Temsirolimus | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.070 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.060 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.040 | Inavolisib | — uncovered |
| APOPTOSIS | 0.010 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.010 | Inavolisib | — uncovered |